Cargando…
Targeting chemokines for acute lymphoblastic leukemia therapy
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981899/ https://www.ncbi.nlm.nih.gov/pubmed/33743810 http://dx.doi.org/10.1186/s13045-021-01060-y |
_version_ | 1783667607970250752 |
---|---|
author | Hong, Zixi Wei, Zimeng Xie, Tian Fu, Lin Sun, Jiaxing Zhou, Fuling Jamal, Muhammad Zhang, Qiuping Shao, Liang |
author_facet | Hong, Zixi Wei, Zimeng Xie, Tian Fu, Lin Sun, Jiaxing Zhou, Fuling Jamal, Muhammad Zhang, Qiuping Shao, Liang |
author_sort | Hong, Zixi |
collection | PubMed |
description | Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines that regulate migration, positioning and interactions of cells. Many chemokine axes such as CXCL12/CXCR4 and CCL25/CCR9 have been proved to play important roles in leukemia microenvironment and further affect ALL outcomes. In this review, we summarize the chemokines that are involved in ALL progression and elaborate on their roles and mechanisms in leukemia cell proliferation, infiltration, drug resistance and disease relapse. We also discuss the potential of targeting chemokine axes for ALL treatments, since many related inhibitors have shown promising efficacy in preclinical trials, and some of them have entered clinical trials. |
format | Online Article Text |
id | pubmed-7981899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79818992021-03-22 Targeting chemokines for acute lymphoblastic leukemia therapy Hong, Zixi Wei, Zimeng Xie, Tian Fu, Lin Sun, Jiaxing Zhou, Fuling Jamal, Muhammad Zhang, Qiuping Shao, Liang J Hematol Oncol Review Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines that regulate migration, positioning and interactions of cells. Many chemokine axes such as CXCL12/CXCR4 and CCL25/CCR9 have been proved to play important roles in leukemia microenvironment and further affect ALL outcomes. In this review, we summarize the chemokines that are involved in ALL progression and elaborate on their roles and mechanisms in leukemia cell proliferation, infiltration, drug resistance and disease relapse. We also discuss the potential of targeting chemokine axes for ALL treatments, since many related inhibitors have shown promising efficacy in preclinical trials, and some of them have entered clinical trials. BioMed Central 2021-03-20 /pmc/articles/PMC7981899/ /pubmed/33743810 http://dx.doi.org/10.1186/s13045-021-01060-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Hong, Zixi Wei, Zimeng Xie, Tian Fu, Lin Sun, Jiaxing Zhou, Fuling Jamal, Muhammad Zhang, Qiuping Shao, Liang Targeting chemokines for acute lymphoblastic leukemia therapy |
title | Targeting chemokines for acute lymphoblastic leukemia therapy |
title_full | Targeting chemokines for acute lymphoblastic leukemia therapy |
title_fullStr | Targeting chemokines for acute lymphoblastic leukemia therapy |
title_full_unstemmed | Targeting chemokines for acute lymphoblastic leukemia therapy |
title_short | Targeting chemokines for acute lymphoblastic leukemia therapy |
title_sort | targeting chemokines for acute lymphoblastic leukemia therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981899/ https://www.ncbi.nlm.nih.gov/pubmed/33743810 http://dx.doi.org/10.1186/s13045-021-01060-y |
work_keys_str_mv | AT hongzixi targetingchemokinesforacutelymphoblasticleukemiatherapy AT weizimeng targetingchemokinesforacutelymphoblasticleukemiatherapy AT xietian targetingchemokinesforacutelymphoblasticleukemiatherapy AT fulin targetingchemokinesforacutelymphoblasticleukemiatherapy AT sunjiaxing targetingchemokinesforacutelymphoblasticleukemiatherapy AT zhoufuling targetingchemokinesforacutelymphoblasticleukemiatherapy AT jamalmuhammad targetingchemokinesforacutelymphoblasticleukemiatherapy AT zhangqiuping targetingchemokinesforacutelymphoblasticleukemiatherapy AT shaoliang targetingchemokinesforacutelymphoblasticleukemiatherapy |